Aventy50 mg

Aventy 50 mg is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction

Drugs for Erectile Dysfunction

Aventy 50 mg is a selective phosphodiesterase 5 (PDE5) enzyme inhibitor used for the treatment of erectile dysfunction caused by diabetes, age induced oxidative stress or other complications. Aventy 50 mg inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by Aventy 50 mg enhances erectile function by increasing the amount of cGMP.

For most patients, the starting dose is 100 mg taken approximately 30 minutes before sexual activity, on an as needed basis. Aventy 50 mg may be taken with or without food. Take Aventy 50 mg no more than once a dayThe dose may be increased to 200 mg or decreased to 50 mg based on efficacy and/or tolerability. Use the lowest dose that provides benefitDo not use Aventy 50 mg with strong CYP3A4 inhibitors. If taking a moderate CYP3A4 inhibitor, the dose should be no more than 50 mg in a 24-hour period. In patients on stable alpha-blocker therapy, the recommended starting dose of Aventy 50 mg is 50 mg

For most patients, the starting dose is 100 mg taken approximately 30 minutes before sexual activity, on an as needed basis. Aventy 50 mg may be taken with or without food. Take Aventy 50 mg no more than once a dayThe dose may be increased to 200 mg or decreased to 50 mg based on efficacy and/or tolerability. Use the lowest dose that provides benefitDo not use Aventy 50 mg with strong CYP3A4 inhibitors. If taking a moderate CYP3A4 inhibitor, the dose should be no more than 50 mg in a 24-hour period. In patients on stable alpha-blocker therapy, the recommended starting dose of Aventy 50 mg is 50 mg

Aventy 50 mg can potentiate the hypotensive effect of nitrates, alphablockers, antihypertensives, and alcohol. CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, erythromycin) increase Aventy 50 mg exposure

Administration of Aventy 50 mg to patients using any form of organic nitrate is contraindicated. Hypersensitivity to any component of the Aventy 50 mg tablet

Most common adverse reactions (greater than or equal to 2%) include headache, flushing, nasal congestion, nasopharyngitis, and back pain

Pregnancy Category C. Aventy 50 mg is not indicated for use in women. There are no adequate and well-controlled studies of Aventy 50 mg in pregnant women.

Patients should not use Aventy 50 mg if sexual activity is inadvisable due to cardiovascular status or any other reason Use of Aventy 50 mg with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotensionPatients should seek emergency treatment if an erection lasts greater than 4 hoursPatients should stop Aventy 50 mg and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of Non Arteritic Ischemic Optic Neuropathy (NAION). Discuss with patients the increased risk of NAION in patients with a history of NAIONPatients should stop taking Aventy 50 mg and seek prompt medical attention in the event of sudden decrease or loss of hearing

Single doses up to 800 mg have been given to healthy subjects, and multiple doses up to 300 mg have been given to patients. In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance because Aventy 50 mg is highly bound to plasma proteins and is not significantly eliminated in the urine.

Store at 20-25°C

Pediatric Use: STENDRA is not indicated for use in pediatric patients. Safety and efficacy in patients below the age of 18 years has not been established.Geriatric Use: Of the total number of subjects in clinical studies of Aventy 50 mg, approximately 23% were 65 and over. No overall differences in efficacy and safety were observed between subjects over 65 years of age compared to younger subjects; therefore no dose adjustment is warranted based on age alone. However, a greater sensitivity to medication in some older individuals should be considered Renal & hepatic impairment patients: Do not use in patients with severe renal & hepatic impairment

Drugs for Erectile Dysfunction

Aventy 50 mg is a selective phosphodiesterase 5 (PDE5) enzyme inhibitor used for the treatment of erectile dysfunction caused by diabetes, age induced oxidative stress or other complications. Aventy 50 mg inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by Aventy 50 mg enhances erectile function by increasing the amount of cGMP.

Pregnancy Category C. Aventy 50 mg is not indicated for use in women. There are no adequate and well-controlled studies of Aventy 50 mg in pregnant women.

Pediatric Use: STENDRA is not indicated for use in pediatric patients. Safety and efficacy in patients below the age of 18 years has not been established.Geriatric Use: Of the total number of subjects in clinical studies of Aventy 50 mg, approximately 23% were 65 and over. No overall differences in efficacy and safety were observed between subjects over 65 years of age compared to younger subjects; therefore no dose adjustment is warranted based on age alone. However, a greater sensitivity to medication in some older individuals should be considered Renal & hepatic impairment patients: Do not use in patients with severe renal & hepatic impairment